Sanofi's diabetes business affected by Q4 falling prices and Covid-19

Sanofi's diabetes business retreated in Q4 of 2020 due to decreased prices and coronavirus.


French pharmaceutical company Sanofi has published its fiscal report for Q4 2020, and even though the firm reports a 4.2-percent growth in sales for the business leg over the course of the fourth quarter, the picture is less rosy in view of the diabetes business.

The French firm has registered a total 8.4-percent decline in the diabetes business, which brings the revenue for the year's final quarter to EUR 1.087bn (USD 1.3bn).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs